Drug Profile

VRDN 003

Alternative Names: VRDN-003

Latest Information Update: 18 Sep 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Viridian Therapeutics
Class Eye disorder therapies; Monoclonal antibodies
Mechanism of Action IGF type 1 receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase III Graves ophthalmopathy

Most Recent Events

15 Sep 2025 Viridian Therapeutics completes enrolment in the REVEAL-1 phase III trial for Graves ophthalmopathy (Thyroid Eye Disease) in USA (NCT06625411)
15 Sep 2025 Viridian Therapeutics completes enrolment in the REVEAL-2 phase III trial for Graves ophthalmopathy in USA (SC, Injection) (NCT06625398)
07 Aug 2025 ZAI Labs plans a registrational study in thyroid eye disease in China in the second half of 2025

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com